Adrián Vizoso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adrián Vizoso has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Albert Garcia-Casanovas
Perioperative Medicine Research Group, Hospital del Mar Research Institute, 08003 Barcelona, Spain
2 shared publications - Ester Miralpeix
Department of Obstetrics and Gynecology, Gynecological Cancer Multidisciplinary Unit, Hospital del Mar Research Institute, Barcelona, Spain; Pompeu Fabra University, Faculty of Medicine and Life Science, Barcelona, Spain
2 shared publications - María José Colomina
Department of Anesthesiology, Bellvitge University Hospital, 08907 L’Hospitalet de Llobregat, Spain
2 shared publications - Misericordia Basora
Department of Anaesthesiology, Hospital Clinic, Barcelona, Spain
2 shared publications - Aleidis Caro-Tarrago
General and Digestive Surgery Department, Joan XXIII University Hospital, Tarragona, Spain
1 shared publication Alicia Aranguren Azparren
1 shared publication
Latest Publications
- Open Access
- 5 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8632
When “Normal” Hemoglobin May Not Be Enough: Sex-Specific Anemia Thresholds and Outcomes in Cardiac Surgery
Background/Objectives: Sex-specific anemia criteria classify women with hemoglobin (Hb) 12.0–12.9 g/dL as non-anemic. We assessed whether World Health Organization (WHO) criteria underrecognize red blood cell (RBC) transfusion risk compared with a uniform patient blood management (PBM) threshold of Hb p < 0.001), whereas the continuous interaction was not (p = 0.486). Sex did not significantly modify the Hb associations with complications or in-hospital mortality within 30 days. Conclusions: Women with Hb 12.0–12.9 g/dL had substantial transfusion risk despite being classified as non-anemic by the WHO criteria. Hb <13.0 g/dL may be a pragmatic sex-inclusive trigger for perioperative risk recognition and etiologic evaluation, not a proven therapeutic target.
- 5 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8632
Open AccessWhen “Normal” Hemoglobin May Not Be Enough: Sex-Specific Anemia Thresholds and Outcomes in Cardiac Surgery
Background/Objectives: Sex-specific anemia criteria classify women with hemoglobin (Hb) 12.0–12.9 g/dL as non-anemic. We assessed whether World Health Organization (WHO) criteria underrecognize red blood cell (RBC) transfusion risk compared with a uniform patient blood management (PBM) threshold of Hb p < 0.001), whereas the continuous interaction was not (p = 0.486). Sex did not significantly modify the Hb associations with complications or in-hospital mortality within 30 days. Conclusions: Women with Hb 12.0–12.9 g/dL had substantial transfusion risk despite being classified as non-anemic by the WHO criteria. Hb <13.0 g/dL may be a pragmatic sex-inclusive trigger for perioperative risk recognition and etiologic evaluation, not a proven therapeutic target.
- 5 September 2025
- Published by Elsevier in The American Journal of Surgery
- Vol. 249, 116603
Postoperative serum VEGF concentration and recurrence after curative colon cancer surgery: findings from a multicenter prospective cohort
- 5 September 2025
- Published by Elsevier in The American Journal of Surgery
- Vol. 249, 116603
Postoperative serum VEGF concentration and recurrence after curative colon cancer surgery: findings from a multicenter prospective cohort
- Open Access
Influence of Age on Treatment and Prognosis in Ovarian Cancer Patients
Background: Ovarian cancer, particularly in advanced stages, requires cytoreductive surgery followed by chemotherapy. A significant proportion of patients are elderly, yet older women are often treated with non-standard regimens despite a lack of consistent evidence linking age to prognosis. The aim of this study is to assess age-specific differences in treatment and survival outcomes for ovarian cancer in women aged 70 years or older. Methods: This retrospective study included ovarian cancer patients treated at the Hospital del Mar, Barcelona, between 2016 and 2022. Patients were stratified into two groups: p = 0.012). Patients aged ≥70 were more likely to undergo interval surgery (p = 0.053) and receive non-standard treatment (p = 0.023). Complete cytoreduction was achieved in 95.8% of younger patients versus 81.3% of older patients (p = 0.024). Age ≥70 did not significantly impact DFS (p = 0.091), but OS was significantly worse in the older group (44.4% vs. 67.2%, p = 0.014). Conclusions: Older women (≥70 years) with ovarian cancer are more likely to be diagnosed at advanced stages, receive non-standard treatment, and achieve suboptimal cytoreduction compared to younger patients. While DFS was similar across age groups, older age was associated with worse OS, highlighting the need for age-tailored treatment strategies.
Open AccessInfluence of Age on Treatment and Prognosis in Ovarian Cancer Patients
Background: Ovarian cancer, particularly in advanced stages, requires cytoreductive surgery followed by chemotherapy. A significant proportion of patients are elderly, yet older women are often treated with non-standard regimens despite a lack of consistent evidence linking age to prognosis. The aim of this study is to assess age-specific differences in treatment and survival outcomes for ovarian cancer in women aged 70 years or older. Methods: This retrospective study included ovarian cancer patients treated at the Hospital del Mar, Barcelona, between 2016 and 2022. Patients were stratified into two groups: p = 0.012). Patients aged ≥70 were more likely to undergo interval surgery (p = 0.053) and receive non-standard treatment (p = 0.023). Complete cytoreduction was achieved in 95.8% of younger patients versus 81.3% of older patients (p = 0.024). Age ≥70 did not significantly impact DFS (p = 0.091), but OS was significantly worse in the older group (44.4% vs. 67.2%, p = 0.014). Conclusions: Older women (≥70 years) with ovarian cancer are more likely to be diagnosed at advanced stages, receive non-standard treatment, and achieve suboptimal cytoreduction compared to younger patients. While DFS was similar across age groups, older age was associated with worse OS, highlighting the need for age-tailored treatment strategies.
- 12 August 2024
- Published by Taylor & Francis in Climacteric
- Vol. 27 (5) , 489-493
COVID-19 vaccination and postmenopausal bleeding: a retrospective cohort study
COVID-19 vaccination has been related to menstrual irregularities; however, the effect on postmenopausal women is unknown. The aim of this study was to analyze the prevalence of postmenopausal bleeding (PMB) after COVID-19 vaccination. A retrospective study was conducted in the Department of Gynecology in Hospital del Mar. Consecutive postmenopausal women with data available and endometrial biopsy were included between February 2021 and January 2022. Patients were stratified between COVID-19 vaccinated and unvaccinated groups. PMB after 30 days from last vaccine dose was considered unrelated to vaccine. Endometrial pathology diagnoses were stratified into benign or malignant. Univariable and multivariable of regression analysis on variables potentially associated with PMB was performed. A total of 381 patients were included, 91 in the vaccinated group and 290 in the unvaccinated group. Prevalence of PMB in the vaccinated group was 75.8% compared to 59.0% in the unvaccinated group (p < 0.005). No increase in endometrial malignant pathology was observed among the vaccinated group (p = 0.189). Multivariable analysis that correlates factors associated with PMB suggests COVID-19 vaccine and malignant endometrial biopsy as independent risk variables. A higher prevalence of PMB was associated with COVID-19 vaccine. Endometrial histological results showed no association with COVID-19 vaccination, but endometrial biopsy should be performed for PMB.
- 12 August 2024
- Published by Taylor & Francis in Climacteric
- Vol. 27 (5) , 489-493
COVID-19 vaccination and postmenopausal bleeding: a retrospective cohort study
COVID-19 vaccination has been related to menstrual irregularities; however, the effect on postmenopausal women is unknown. The aim of this study was to analyze the prevalence of postmenopausal bleeding (PMB) after COVID-19 vaccination. A retrospective study was conducted in the Department of Gynecology in Hospital del Mar. Consecutive postmenopausal women with data available and endometrial biopsy were included between February 2021 and January 2022. Patients were stratified between COVID-19 vaccinated and unvaccinated groups. PMB after 30 days from last vaccine dose was considered unrelated to vaccine. Endometrial pathology diagnoses were stratified into benign or malignant. Univariable and multivariable of regression analysis on variables potentially associated with PMB was performed. A total of 381 patients were included, 91 in the vaccinated group and 290 in the unvaccinated group. Prevalence of PMB in the vaccinated group was 75.8% compared to 59.0% in the unvaccinated group (p < 0.005). No increase in endometrial malignant pathology was observed among the vaccinated group (p = 0.189). Multivariable analysis that correlates factors associated with PMB suggests COVID-19 vaccine and malignant endometrial biopsy as independent risk variables. A higher prevalence of PMB was associated with COVID-19 vaccine. Endometrial histological results showed no association with COVID-19 vaccination, but endometrial biopsy should be performed for PMB.
- 25 June 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 133 (3) , 637-646
Hospital variation in quality indicators for patient blood management in total knee and hip arthroplasty: a retrospective cohort study
- 25 June 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 133 (3) , 637-646
Hospital variation in quality indicators for patient blood management in total knee and hip arthroplasty: a retrospective cohort study